GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EyePoint Pharmaceuticals Inc (STU:PV3B) » Definitions » Shiller PE Ratio

EyePoint Pharmaceuticals (STU:PV3B) Shiller PE Ratio : (As of May. 21, 2024)


View and export this data going back to 2009. Start your Free Trial

What is EyePoint Pharmaceuticals Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


EyePoint Pharmaceuticals Shiller PE Ratio Historical Data

The historical data trend for EyePoint Pharmaceuticals's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EyePoint Pharmaceuticals Shiller PE Ratio Chart

EyePoint Pharmaceuticals Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

EyePoint Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of EyePoint Pharmaceuticals's Shiller PE Ratio

For the Biotechnology subindustry, EyePoint Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


EyePoint Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EyePoint Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where EyePoint Pharmaceuticals's Shiller PE Ratio falls into.



EyePoint Pharmaceuticals Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

EyePoint Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, EyePoint Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.506/131.7762*131.7762
=-0.506

Current CPI (Mar. 2024) = 131.7762.

EyePoint Pharmaceuticals Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 -1.030 100.560 -1.350
201409 5.199 100.428 6.822
201412 -1.135 99.070 -1.510
201503 -1.571 99.621 -2.078
201506 -1.515 100.684 -1.983
201509 -1.515 100.392 -1.989
201512 -1.652 99.792 -2.181
201603 -1.347 100.470 -1.767
201606 -1.691 101.688 -2.191
201609 -1.871 101.861 -2.420
201612 -0.019 101.863 -0.025
201703 -1.402 102.862 -1.796
201706 -1.424 103.349 -1.816
201709 -1.259 104.136 -1.593
201712 -1.098 104.011 -1.391
201803 -1.216 105.290 -1.522
201806 -5.307 106.317 -6.578
201809 -3.771 106.507 -4.666
201812 -0.791 105.998 -0.983
201903 -1.770 107.251 -2.175
201906 -0.974 108.070 -1.188
201909 -1.362 108.329 -1.657
201912 -0.900 108.420 -1.094
202003 -1.032 108.902 -1.249
202006 -0.924 108.767 -1.119
202009 -0.255 109.815 -0.306
202012 -0.880 109.897 -1.055
202103 -0.420 111.754 -0.495
202106 -0.291 114.631 -0.335
202109 -0.493 115.734 -0.561
202112 -0.522 117.630 -0.585
202203 -0.508 121.301 -0.552
202206 -0.492 125.017 -0.519
202209 -0.495 125.227 -0.521
202212 -1.095 125.222 -1.152
202303 -0.523 127.348 -0.541
202306 -0.563 128.729 -0.576
202309 -0.309 129.860 -0.314
202312 -0.293 129.419 -0.298
202403 -0.506 131.776 -0.506

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


EyePoint Pharmaceuticals  (STU:PV3B) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


EyePoint Pharmaceuticals Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of EyePoint Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


EyePoint Pharmaceuticals (STU:PV3B) Business Description

Traded in Other Exchanges
Address
480 Pleasant Street, Suite B300, Watertown, MA, USA, 02472
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.

EyePoint Pharmaceuticals (STU:PV3B) Headlines

No Headlines